Education and training

Main priorities for the development of geriatric oncology: A worldwide expert perspective

Martine Extermann*, Matti Aapro, Riccardo Audisio, Lodovico Balducci, Jean-Pierre Droz, Christopher Steer, Hans Wildiers, Gilbert Zulian

On behalf of the International Society of Geriatric Oncology (SIGO)

ARTICLE INFO

Objective: The world population is aging rapidly, thanks to improvements in nutrition, sanitation, disease treatment and prevention (notably for infectious diseases), and better economic conditions. As aging is the main risk factor for cancer, its incidence follows suit. This represents a worldwide challenge and addressing it correctly will require a vast international effort and clear priorities.

Methods: The International Society of Geriatric Oncology (SIGO), a multidisciplinary society of experts in the field, decided to identify those priorities. The SIGO National Representatives (NRs) were asked first to identify the 10 highest priorities to address on a worldwide scale. Then, the NRs were asked to identify how these priorities were/could be implemented in their country. A writing committee assembled and edited the results.

Results: We identified 3 key areas of priority: education, clinical practice, and research. Education should be targeted at both the professional and the population levels. In clinical practice, pilot-models of multidisciplinary collaboration should be expanded first to key reference centers, and a 2-step approach to screening and evaluation should be used to optimize resource use. In research, several strategies can render trials more relevant for older patients. These priorities are fully detailed in a monograph† that can be viewed online at www.siog.org or ordered from siog@emontier.net. This article explores the rationale and general academic and public health implications of these priorities.

Conclusions: These priorities represent an expert consensus with potential to guide education, clinical practice, and research to improve the care of older cancer patients throughout the world.

© 2011 Elsevier Ltd. All rights reserved.

Contents

1. Introduction ................................................................. 271
2. Methods ................................................................. 271
3. Results ................................................................. 271
   3.1. Education ........................................................ 271
   3.2. Clinical Practice ............................................... 271
   3.3. Research .......................................................... 272

* Corresponding author at: Senior Adult Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. Tel.: +1 813 745 3822; fax: +1 813 745 1908.
E-mail address: martine.extermann@moffitt.org (M. Extermann).

1879-4068/$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.jgo.2011.07.001
1. Introduction

Thanks to the global improvement in health care and living conditions, the world’s population is aging. In developed countries, half of the cancers already occur in patients aged 70 and older, so geriatric oncology is rapidly coming to the foreground of oncology practice. In booming Asian nations, such as South Korea or Japan, the aging trend is particularly striking. In fact, by 2050 the majority of older persons will live in developing countries. As older patients have a very variable health status, the need for proper integration of an oncologic and a geriatric approach has become increasingly important. Incorporating geriatric principles into routine oncology care will serve to optimize the treatment and reduce the functional impairment of older cancer patients and the associated social and personal costs. Given the size of the problem, governmental health agencies, international and local organizations, academic institutions, and the medical community at large will need to identify and target the most pressing issues. Expert input is invaluable in this process, and therefore SIOG decided to create a consensus statement of the top priorities within the field of geriatric oncology, after consultation with members from around the globe.

2. Methods

Over 2009 and 2010, SIOG asked its national representatives (see list in Appendix A) to identify the top 10 global priorities in the field of geriatric oncology. Their answers were collected by a writing committee and a consensus was built. A second round of questions was then circulated asking the representatives to comment on how practically these priorities would translate more concretely in their national setting. The writing committee then assembled the answers and redacted a region by region translation of the 10 global priorities. All national representatives had the opportunity to review the final manuscript.

3. Results

The 10 priorities are listed in Table 1, and can be organized in three key domains: education, clinical practice, and research.

3.1. Education

Education should be targeted at both the population and the professional levels. We will need to learn to manage the rapid aging of the world population and its accompanying hundreds of millions impending cases of cancer. A broad development of education concerning the needs of older cancer patients is therefore necessary. Life expectancy has significantly increased thanks to improved health care, but is often underestimated by physicians and patients. For example, whereas the life expectancy at birth in their country is often known by inhabitants, few people realize that an average 65-year-old woman can expect to live another 20 years, and that in developed countries an average 80-year-old has a 30 to 40% chance of reaching 90 years of age. The specific educational needs might vary from country to country. In many countries, there is undertreatment of older cancer patients due to the belief that treatments won’t be effective or will be too toxic in the elderly. As therapeutic options diversify rapidly in oncology (e.g. targeted therapies, local treatments for liver metastases, stereotactic radiation therapy) and both supportive care and palliative care improve, it is important to make physicians, authorities and the general public aware that cancer treatment is not a one-size-fits-all proposition and that many approaches can be adapted to an older person. Furthermore, by preventing or delaying functional dependence, appropriate cancer treatments can contribute to decreasing the costs engendered by the cancer and its related complications.

As cancer is becoming the first cause of mortality in the elderly, we need to make adequate room for it in our training programs for physicians, nurses, and allied health professionals, especially those involved in geriatrics. More emphasis on the principles of cancer care and follow-up will be required in the graduate and post-graduate continuing education of every physician.

3.2. Clinical Practice

Older adults represent the majority of cancer patients and survivors in developed countries and a rapidly growing proportion of patients in developing countries. There is therefore a dual need for: a) more specialized geriatric oncology units, and b) similar to cardiovascular disease or diabetes, a need for general education of oncologists on the principles of geriatric oncology. One important principle is the need for adequate assessment of older adults with cancer. Increasingly a two-step approach to assessment is emerging in clinical practice. Initially some form of short screening tool is recommended for every new older cancer patient and, for the patients with a positive screening test, a more thorough multidisciplinary team assessment and management. An adequate assessment with an integrated intervention plan is the cornerstone of appropriate care of older cancer patients. Geriatric oncology units and programs have been developing rapidly, in different formats, over the last decade. It is the strong conviction of the SIOG experts that each academic center and major cancer center should have a multidisciplinary geriatric oncology team. Such units and programs should also conduct elderly-targeted research. A strong priority for the development of clinical practice is to develop practical ways to integrate
Table 1 – Worldwide priorities to address cancer in the elderly.

<table>
<thead>
<tr>
<th>Priority</th>
<th>Description</th>
</tr>
</thead>
</table>
| Education | 1. Increase public awareness of the worldwide cancer in the elderly epidemic and the need for a specific approach to address the problem  
2. Political institutions (health ministries, international organizations)  
3. Medical societies  
4. Advocacy networks, media, to develop a more positive image of older cancer patients  
5. Integrate geriatric oncology in the curricula for medical and nursing education, both during studies and post-graduate education  
6. Address the shortage of specialist oncologist/geriatricians and allied health staff in geriatric oncology  
7. Develop/support specific training programs  
8. Increase/develop funding to foster academically oriented specialists able to address the populations not targeted by traditional oncology studies |
| Clinical practice | 4. Develop interdisciplinary geriatric oncology clinics, especially in academic institutions and comprehensive cancer centers  
5. Integrate geriatric evaluation (including comorbidities) into oncology decision-making and guidelines  
6. Address issues of access to care, including the needs of the caregiver |
| Research | 7. Develop, test, and disseminate easy screening tools to enable proper referrals to multidisciplinary clinics and encourage integrated approaches between oncologist and geriatricians  
8. Create a clear and operational definition of vulnerability/frailty applicable to oncology  
9. Increase the relevance of clinical trials for older patients:  
- Require large phase III trials to oversample older cancer patients in order reach a meaningful percentage of their cohorts, and to structure their analyses to provide results specific and pertinent to this population  
- Extend phase II and III trials to patients with high levels of comorbidity or functional impairment with stratified accruals or extension cohorts  
- Design specific trials for older cancer patients |
| 10. Promote multidisciplinary, basic/translational research on the interface of aging and cancer. |

3.3. Research

The elderly are a population that has long been underserved in cancer research. The reasons are several, but it is crucial that the trend be changed. Beside the epidemiologic challenge of an aging population, older patients from at least two continents are interested in standard therapy options. Yet, the standard approach to clinical trials (i.e., the traditional phase II/III general study) has consistently understudied older patients, and those who are included are a healthy selected subgroup. Given the high prevalence of comorbidity in the elderly, it is an ethical necessity that new approaches be developed to study treatments appropriate for the bulk of our target population, especially in cooperative groups. Original study designs such as studies specifically targeting older patients, studies with stratified accrual based on predictors of treatment toxicity or frailty indexes, or studies requiring that a significant subgroup of older patients be included, should be developed.

This said work remains to be done on the tailoring of geriatric instruments to the oncology patients, and the specifics of decision making in this field. For example, geriatric attempts at defining frailty usually aim at identifying a population at high risk of dying or becoming dependent in the short term. However, a definition that would address end-points such as the ability to tolerate combined chemo-radiation, chemotherapy, or surgery would be very helpful. Of particular interest in oncology is the identification of the vulnerable patient: the patient who appears healthy enough for active treatments to be considered, but is at high risk of decompensating. As refining these definitions would be crucial in the performance of clinical trials and in optimally guiding individualized therapy, we list it as a priority.

Another research priority, in the era of personalized cancer care relying heavily on genomics, epigenomics, proteomics and metabolomics, is to harness the synergistic potential of basic and translational research in both aging and cancer. In many ways, the development of a cancer can be defined as “senescence gone bad.” A challenge of whole genome analysis for example is the overwhelming quantity of data to sort out. Separating the “locomotive” mechanism from the wagon is difficult. We believe that if a mechanism demonstrates a role in both aging and cancer, that mechanism is more likely to be a key mechanism in the cellular control/ transformation process. This might spare research from pursuing several blind alleys. In the same line of reasoning, most cancer therapies are tested in young mice and other animals prior to be launched into
phase I studies. The yield of phase I studies in effective and safe
drugs is disappointing to say the least. We might learn more
about response rates and toxic effects by investigating new
drugs in old animals, but unfortunately this approach has been
poorly studied so far.

4. Conclusion

Cancer in older patients is not an issue limited to developed
countries but is rapidly becoming a worldwide phenomenon.
Recently, the WHO emphasized that chronic illnesses, cancer
among them, have surpassed infectious diseases as a global
threat: non communicable diseases accounted for 63% of global
deaths in 2008, and nearly 80% of these occurred in low and
middle-income countries8. In its 2008 World Cancer Declaration,
the International Union against Cancer (UICC) established a
number of targets that they thought should be achieved by 2020.
One of these targets was to "Access to accurate cancer diagnosis,
appropriate cancer treatments, supportive care, rehabilitation
services and palliative care will have improved for all
patients worldwide". With the 10 priorities initiative, SIOG
provides a framework of concrete issues that should be
addressed to enhance the development of the field of geriatric
oncology. The ultimate goals are to improve the outcome of our
older cancer patients, and to optimize the use of health care
resources.

Disclosures

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conception and design: ME, JPD.
Data collection: See Appendix A.
Analysis and interpretation: ME, MA, RA, LB, JPD, CS, HW, GZ.
Writing and final approval: ME, MA, RA, LB, JPD, CS, HW, GZ.

Appendix A

The following SIOG members contributed to this project:

<table>
<thead>
<tr>
<th>Project leader:</th>
<th>Martine Extermann</th>
</tr>
</thead>
<tbody>
<tr>
<td>Writing Committee:</td>
<td>Matti Aapro</td>
</tr>
<tr>
<td></td>
<td>Riccardo Audisio</td>
</tr>
<tr>
<td></td>
<td>Lodovico Balducci</td>
</tr>
<tr>
<td></td>
<td>Jean-Pierre Droz</td>
</tr>
<tr>
<td></td>
<td>Christopher Steer</td>
</tr>
<tr>
<td></td>
<td>Hans Wildiers</td>
</tr>
<tr>
<td></td>
<td>Gilbert Zulian</td>
</tr>
</tbody>
</table>

National representatives and other participants
"Denotes current NRs
Salah-Eldin Abdelmoneim (Egypt)*
Lodovico Balducci (USA)*
Giordano Domenico Beretta (Italy)

Jan Willem Coebergh (The Netherlands)
Hervé Curé (France)*
Kazuo Dan (Japan)*
Beena Devi (Malaysia)*
Alexandru Grigorescu (Romania)*
Jørn Herrstedt (Denmark)*
Arti Hurria (USA)
Maryska Janssen-Heijn (The Netherlands)
Dimitrios Kardamakis (Greece)*
Siri Kristiansson (Norway)*
Jean Latrelle (Canada)*
Robert Leonard (United Kingdom)*
Stuart Lichtman (USA)*
Vicki Morrison (USA)*
Arash Naeim (USA)*
Hans Mortier (The Netherlands)*
Deirdre O'Donnell (Ireland)*
Demetris Papanicolaou (Cyprus)*
Purush Parikh (India)*
Guemersindo Perez Manga (Spain)*
Donald Poon (Singapore)*
Reinhard Stauder (Austria)*
Christopher Steer (Australia)*
Maria Wagnerova (Slovakia)*
Ulrich Wedding (Germany)*
Hans Wildiers (Belgium)*
Manuela Zereu (Brazil)*
Gilbert Zulian (Switzerland)*

References